Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria de Navarra (14)

2024

  1. Nigrostriatal degeneration determines dynamics of glial inflammatory and phagocytic activity

    Journal of Neuroinflammation, Vol. 21, Núm. 1

2023

  1. Microglia and astrocyte activation is region-dependent in the α-synuclein mouse model of Parkinson's disease

    GLIA, Vol. 71, Núm. 3, pp. 571-587

  2. Stabilization of 14-3-3 protein-protein interactions with Fusicoccin-A decreases alpha-synuclein dependent cell-autonomous death in neuronal and mouse models

    Neurobiology of Disease, Vol. 183

2021

  1. Expression of endothelial nox5 alters the integrity of the blood-brain barrier and causes loss of memory in aging mice

    Antioxidants, Vol. 10, Núm. 8

  2. Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis

    Acta Neuropathologica Communications, Vol. 9, Núm. 1

2020

  1. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease

    Diagnosis and Management in Parkinson’s Disease: The Neuroscience of Parkinson’s Disease, Volume 1 (Elsevier), pp. 557-573

  2. Cb2 receptors and neuron–glia interactions modulate neurotoxicity generated by magl inhibition

    Biomolecules, Vol. 10, Núm. 8, pp. 1-15

2019

  1. Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions

    Journal of Neuroinflammation, Vol. 16, Núm. 1

2018

  1. The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia

    Neurobiology of Disease, Vol. 118, pp. 64-75

2017

  1. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  2. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

    Neuropharmacology, Vol. 113, pp. 110-123

  3. Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks

    Neuroscience and Biobehavioral Reviews, Vol. 76, pp. 380-395

2016

  1. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

  2. Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors

    Molecular Neurobiology, Vol. 53, Núm. 4, pp. 2312-2319